InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) - Announcements

Current share price for NSB : $0.063 0.002 (3.28%)+

ASX company news and announcements for NeuroScientific Biopharmaceuticals Ltd (NSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All NeuroScientific Biopharmaceuticals Ltd (NSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than NeuroScientific Biopharmaceuticals Ltd (NSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for NeuroScientific Biopharmaceuticals Ltd (NSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$25 Investor Webinar Update 12 Nov 2025 10:00AM $0.135 $0.063 fallen by 53.33%
$25 Fourth Patient Commences StemSmart MSC Treatment 11 Nov 2025 9:26AM $0.140 $0.063 fallen by 55%
$25 Clinical & Scientific Advisory Board Appointed 6 Nov 2025 9:28AM $0.125 $0.063 fallen by 49.60%
$25 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2025 9:10AM $0.115 $0.063 fallen by 45.22%
$25 AusBiotech Presentation 21 Oct 2025 9:23AM $0.140 $0.063 fallen by 55%
$25 First Patients Approved for Special Access Program 7 Oct 2025 9:27AM $0.155 $0.063 fallen by 59.35%
$25 Letter to Shareholders & Proxy Form 2 Oct 2025 10:15AM $0.160 $0.063 fallen by 60.63%
$25 Notice of Meeting & Proxy Form 2 Oct 2025 10:15AM $0.160 $0.063 fallen by 60.63%
$25 Ceasing to be a substantial holder 19 Sep 2025 8:56AM $0.165 $0.063 fallen by 61.82%
$25 Date of AGM & Closing Date for Director Nominations 16 Sep 2025 9:46AM $0.180 $0.063 fallen by 65%
$25 Notification regarding unquoted securities - NSB 16 Sep 2025 9:28AM $0.180 $0.063 fallen by 65%
$25 Appendix 4G & Corporate Governance Statement 28 Aug 2025 5:23PM $0.160 $0.063 fallen by 60.63%
$25 2025 Annual Report & Appendix 4E 28 Aug 2025 5:23PM $0.160 $0.063 fallen by 60.63%
$25 Previous StemSmart Studies Support Renal Transplantation 27 Aug 2025 9:49AM $0.165 $0.063 fallen by 61.82%
$25 Presentation - TechKnow Invest Roadshow Conference 19 Aug 2025 8:47AM $0.170 $0.063 fallen by 62.94%
$25 NeuroScientific Partners with Leading Biologic Manufacturer 31 Jul 2025 9:02AM $0.240 $0.063 fallen by 73.75%
$25 Change in substantial holding 30 Jul 2025 10:16AM $0.240 $0.063 fallen by 73.75%
$25 Experienced Cell Therapy Executive Appointed CEO 28 Jul 2025 9:19AM $0.220 $0.063 fallen by 71.36%
$25 Dr Catherine Cole Appointed as Chief Medical Officer 25 Jul 2025 9:19AM $0.230 $0.063 fallen by 72.61%
$25 Quarterly Activities/Appendix 4C Cash Flow Report 23 Jul 2025 9:18AM $0.190 $0.063 fallen by 66.84%
$25 Becoming a substantial holder 10 Jul 2025 3:53PM $0.130 $0.063 fallen by 51.54%
$25 Change in substantial holding 4 Jul 2025 2:13PM $0.130 $0.063 fallen by 51.54%
$25 Change of Director's Interest Notice (AU) 1 Jul 2025 12:50PM $0.120 $0.063 fallen by 47.50%
$25 Breakthrough Stem Cell Tech Acquired-StemSmart Presentation 30 Jun 2025 9:14AM $0.080 $0.063 fallen by 21.25%
$25 StemSmart Acquisition Complete 27 Jun 2025 9:29AM $0.074 $0.063 fallen by 14.86%

26 - 50 of 413 results

Page 2 of 17

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.